|
The average cost of bringing a new molecule to FDA approval has risen precipitously during the last 10 years.
The average cost of bringing a new molecule to FDA approval has risen precipitously during the last 10 years. In order to control costs, improve efficiencies, and streamline the timeline from discovery to approval, life sciences companies participate in outsourcing collaborations with CROs. Organizations from large pharmaceutical and agricultural companies to virtual companies with no scientific staff make use of CROs in the areas of R&D and manufacturing. In the area of discovery services, all phases are outsourced. Outsourcing also extends through the preclinical development and clinical/manufacturing phases of drug development.
In recent years, clients have begun to take advantage of capabilities and partnering opportunities with CROs at multiple sites across the globe in order to take advantage of cost benefits and regional expertise.
|
